Cytokine Assay for Early Identification of Pediatric Stem Cell Transplant Recipients

The recruitment status of this study is unknown because the information has not been verified recently.
Verified June 2010 by Stanford University.
Recruitment status was  Recruiting
Sponsor:
Information provided by:
Stanford University
ClinicalTrials.gov Identifier:
NCT01135355
First received: June 1, 2010
Last updated: June 15, 2010
Last verified: June 2010

June 1, 2010
June 15, 2010
July 2008
December 2010   (final data collection date for primary outcome measure)
Not Provided
Not Provided
Complete list of historical versions of study NCT01135355 on ClinicalTrials.gov Archive Site
Not Provided
Not Provided
Not Provided
Not Provided
 
Cytokine Assay for Early Identification of Pediatric Stem Cell Transplant Recipients
Cytokine Assay for Early Identification of Pediatric Stem Cell Transplant Recipients at Risk for Respiratory Failure

The aim of our study is to determine whether a clinically relevant laboratory measurement (of seven specific immunologic biochemicals in the blood) can identify which bone marrow transplant recipients are likely to progress to respiratory failure. Our ultimate goal is to devise a comprehensive and inclusive laboratory test that is effective at determining who is likely to go on to respiratory failure, in order to facilitate early medical intervention.

Not Provided
Observational
Observational Model: Cohort
Time Perspective: Prospective
Not Provided
Retention:   Samples With DNA
Description:

blood

Non-Probability Sample

Hematopoietic stem cell transplantation (HSCT) for any indication.

  • Stem Cell Transplantation
  • Blood and Marrow Transplant (BMT)
Not Provided
Not Provided
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruiting
50
July 2011
December 2010   (final data collection date for primary outcome measure)

Inclusion Criteria:- Hematopoietic stem cell transplantation (HSCT) for any indication.

  • Patients will range from age 0 to age 21. There is no gender restriction. We expect the male to female ratio to end up being about 50/50
  • Ability to understand and the willingness to sign a written informed consent document.
Both
up to 21 Years
No
Contact: Kimberly Boynton (650) 498-6713 boynton@stanford.edu
United States
 
NCT01135355
SU-09222008-1301, PEDSBMT199, PEDSHSCT0002
Not Provided
Rajni Agarwal-Hashmi, Stanford University School of Medicine
Stanford University
Not Provided
Principal Investigator: Rajni Agarwal-Hashmi Stanford University
Stanford University
June 2010

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP